The PerPAIN trial: a pilot randomized controlled trial of personalized treatment allocation for chronic musculoskeletal pain-a protocol.
Chronic pain
Personalized allocation
Precision therapy
Psychotherapy
Treatment personalization
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
27
12
2021
accepted:
01
11
2022
entrez:
10
12
2022
pubmed:
11
12
2022
medline:
11
12
2022
Statut:
epublish
Résumé
The therapy of chronic musculoskeletal pain (CMSP) is complex and the treatment results are often insufficient despite numerous therapeutic options. While individual patients respond very well to specific interventions, other patients show no improvement. Personalized treatment assignment offers a promising approach to improve response rates; however, there are no validated cross-disease allocation algorithms available for the treatment of chronic pain in validated personalized pain interventions. This trial aims to test the feasibility and safety of a personalized pain psychotherapy allocation with three different treatment modules and estimate initial signals of efficacy and utility of such an approach compared to non-personalized allocation. This is a randomized, controlled assessor-blinded pilot trial with a multifactorial parallel arm design. CMSP patients (n = 105) will be randomly assigned 1:1 to personalized or non-personalized treatment based on a cluster assignment of the West Haven-Yale Multidimensional Pain Inventory (MPI). In the personalized assignment condition, patients with high levels of distress receive an emotional distress-tailored intervention, patients with pain-related interference receive an exposure/extinction-tailored treatment intervention and patients who adapt relatively well to the pain receive a low-level smartphone-based activity diary intervention. In the control arm, patients receive one of the two non-matching interventions. Effect sizes will be calculated for change in core pain outcome domains (pain intensity, physical and emotional functioning, stress experience, participant ratings of improvement and satisfaction) after intervention and at follow-up. Feasibility and safety outcomes will assess rates of recruitment, retention, adherence and adverse events. Additional data on neurobiological and psychological characteristics of the patients are collected to improve treatment allocation in future studies. Although the call for personalized treatment approaches is widely discussed, randomized controlled trials are lacking. As the personalization of treatment approaches is challenging, both allocation and intervention need to be dynamically coordinated. This study will test the feasibility and safety of a novel study design in order to provide a methodological framework for future multicentre RCTs for personalized pain psychotherapy. German Clinical Trials Register, DRKS00022792 ( https://www.drks.de ). Prospectively registered on 04/06/2021.
Sections du résumé
BACKGROUND
BACKGROUND
The therapy of chronic musculoskeletal pain (CMSP) is complex and the treatment results are often insufficient despite numerous therapeutic options. While individual patients respond very well to specific interventions, other patients show no improvement. Personalized treatment assignment offers a promising approach to improve response rates; however, there are no validated cross-disease allocation algorithms available for the treatment of chronic pain in validated personalized pain interventions. This trial aims to test the feasibility and safety of a personalized pain psychotherapy allocation with three different treatment modules and estimate initial signals of efficacy and utility of such an approach compared to non-personalized allocation.
METHODS
METHODS
This is a randomized, controlled assessor-blinded pilot trial with a multifactorial parallel arm design. CMSP patients (n = 105) will be randomly assigned 1:1 to personalized or non-personalized treatment based on a cluster assignment of the West Haven-Yale Multidimensional Pain Inventory (MPI). In the personalized assignment condition, patients with high levels of distress receive an emotional distress-tailored intervention, patients with pain-related interference receive an exposure/extinction-tailored treatment intervention and patients who adapt relatively well to the pain receive a low-level smartphone-based activity diary intervention. In the control arm, patients receive one of the two non-matching interventions. Effect sizes will be calculated for change in core pain outcome domains (pain intensity, physical and emotional functioning, stress experience, participant ratings of improvement and satisfaction) after intervention and at follow-up. Feasibility and safety outcomes will assess rates of recruitment, retention, adherence and adverse events. Additional data on neurobiological and psychological characteristics of the patients are collected to improve treatment allocation in future studies.
CONCLUSION
CONCLUSIONS
Although the call for personalized treatment approaches is widely discussed, randomized controlled trials are lacking. As the personalization of treatment approaches is challenging, both allocation and intervention need to be dynamically coordinated. This study will test the feasibility and safety of a novel study design in order to provide a methodological framework for future multicentre RCTs for personalized pain psychotherapy.
TRIAL REGISTRATION
BACKGROUND
German Clinical Trials Register, DRKS00022792 ( https://www.drks.de ). Prospectively registered on 04/06/2021.
Identifiants
pubmed: 36494768
doi: 10.1186/s40814-022-01199-6
pii: 10.1186/s40814-022-01199-6
pmc: PMC9732983
doi:
Types de publication
Journal Article
Langues
eng
Pagination
251Subventions
Organisme : BMBF
ID : 01EC1904A
Informations de copyright
© 2022. The Author(s).
Références
Cochrane Database Syst Rev. 2020 Aug 12;8:CD007407
pubmed: 32794606
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003388
pubmed: 17636720
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Spine (Phila Pa 1976). 2000 Nov 15;25(22):2940-52; discussion 2952
pubmed: 11074683
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur J Pain. 2016 Oct;20(9):1478-89
pubmed: 27302744
Psychiatr Prax. 2018 Mar;45(2):59-61
pubmed: 29495051
Pain Med. 2019 Mar 1;20(3):464-475
pubmed: 29701812
Pain. 2017 Apr;158 Suppl 1:S92-S96
pubmed: 28114184
Pain. 2016 Aug;157(8):1799-1809
pubmed: 27075429
Lancet. 2001 Jun 2;357(9270):1763-4
pubmed: 11403816
Lancet. 2021 May 29;397(10289):2082-2097
pubmed: 34062143
Pain. 2016 Sep;157(9):1851-1871
pubmed: 27152687
Schmerz. 1990 Jun;4(2):82-7
pubmed: 18415223
Exp Brain Res. 2012 May;218(4):619-28
pubmed: 22427134
Arthritis Rheum. 2007 Jun 15;57(5):830-6
pubmed: 17530683
Curr Opin Psychiatry. 2016 Jul;29(4):258-63
pubmed: 27153125
Schmerz. 2021 Feb;35(1):21-29
pubmed: 33534105
PLoS One. 2016 Jun 22;11(6):e0157503
pubmed: 27331907
Pain Med. 2014 Feb;15(2):247-63
pubmed: 24308821
Eur Heart J. 2019 May 21;40(20):1609-1617
pubmed: 30859195
J Pain. 2008 Feb;9(2):105-21
pubmed: 18055266
Pain. 2014 Mar;155(3):457-460
pubmed: 24071599
J Consult Clin Psychol. 1988 Apr;56(2):233-8
pubmed: 3372831
J Appl Stat. 2013 Feb 1;40(2):311-319
pubmed: 26989292
Eur J Pain. 2010 Apr;14(4):339
pubmed: 20227310
J Pain Res. 2018 Sep 28;11:2107-2113
pubmed: 30319285
Curr Opin Psychiatry. 2012 Mar;25(2):109-13
pubmed: 22227632
Nature. 2019 Feb;566(7744):339-343
pubmed: 30760920
World Psychiatry. 2018 Jun;17(2):123-132
pubmed: 29856567
Clin J Pain. 2016 Jul;32(7):568-79
pubmed: 26379077
Eur J Pain. 2014 May;18(5):729-39
pubmed: 24327313
Front Psychiatry. 2016 Dec 20;7:201
pubmed: 28066274
Pain. 2013 Sep;154(9):1846-1855
pubmed: 23752177
Lancet. 2018 Jun 9;391(10137):2384-2388
pubmed: 29573871
BMC Musculoskelet Disord. 2012 Aug 03;13:136
pubmed: 22862787